Utama › Kanser Endometrium › Illinois › Chicago
Kajian klinikal Kanser Endometrium di Chicago, IL
25 kajian untuk Kanser Endometrium sedang mencari peserta di lokasi dalam dan sekitar Chicago (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Mengambil pesertaFasa 2
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- dan 3 lagi
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Mengambil pesertaFasa 1
- University of Chicago Comprehensive Cancer Center, Chicago
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Mengambil pesertaFasa 3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 2
- University of Illinois Cancer Center, Chicago
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Mengambil pesertaKajian pemerhatian
- University of Chicago, Chicago
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Mengambil pesertaFasa 1
- Research Site, Chicago
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Mengambil pesertaFasa 1/2
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago Medical Center, Chicago
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Mengambil pesertaFasa 2
- Northwestern University, Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Mengambil pesertaFasa 1
- Northwestern University Feinberg School of Medicine, Chicago
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Mengambil pesertaFasa 3
- University of Chicago Medical Center ( Site 5002), Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Mengambil pesertaFasa 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Mengambil pesertaFasa 1
- University of Chicago Medical Center, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Mengambil pesertaFasa 1/2
- Lurie Children's Hospital-Chicago, Chicago
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Mengambil pesertaFasa 2
- Northwestern Medicine, Chicago
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Mengambil pesertaFasa 1/2
- University of Chicago Medical Center, Chicago
A Study of PHST001 in Advanced Solid Tumors
Mengambil pesertaFasa 1
- University of Chicago Medical Center, Chicago
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Mengambil pesertaFasa 3
- Research Site, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Mengambil pesertaFasa 1/2
- Northwestern University, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
Mengambil pesertaFasa 1
- The University of Chicago Medical Center (UCMC), Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Mengambil pesertaFasa 1/2
- Northwestern Memorial Hospital, Chicago
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
Mengambil peserta
- Northwestern University, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Mengambil pesertaFasa 1/2
- University of Chicago Medical Center, Chicago
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
Mengambil peserta
- Northwestern Memorial Hospital, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Chicago
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
Kajian Kanser Endometrium di bandar lain
- Houston, TX68 kajian
- New York City, NY52 kajian
- Boston, MA50 kajian
- Arlington, VA39 kajian
- Nashville, TN38 kajian
- Los Angeles, CA34 kajian
- St. Louis, MO29 kajian
- Philadelphia, PA28 kajian
- San Antonio, TX27 kajian
- Columbus, OH25 kajian
- Queens, NY25 kajian
- Oklahoma City, OK25 kajian
Kajian lain di Chicago
- Kanser Paru-paru Bukan Sel Kecil61 kajian
- Kanser Payudara58 kajian
- Kanser (semua jenis)51 kajian
- Kanser Metastatik45 kajian
- Kanser Prostat45 kajian
- Obesiti41 kajian
- Kanser Paru-paru41 kajian
- Kanser Ovari36 kajian
- Strok34 kajian
- Kanser Kolorektal33 kajian
- Kegagalan Jantung31 kajian
- Berat Badan Berlebihan28 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.